Sarah Morice

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Sara G Danielli, Jakob Wurth, Sarah Morice, Samanta Kisele, Didier Surdez, Olivier O Delattre, Peter Karl Bode, Marco Wachtel, Beat W Schäfer
Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. Molecular cancer therapeutics 23 (6) (2024)
Sara G Danielli, Jakob Wurth, Sarah Morice, Samanta Kisele, Didier Surdez, Olivier O Delattre, Peter Karl Bode, Marco Wachtel, Beat W Schäfer
Evaluation of the role of AXL in fusion-positive pediatric rhabdomyosarcoma identifies the small-molecule inhibitor bemcentinib (BGB324) as potent chemosensitizer. Molecular cancer therapeutics (2024)
Sara G Danielli, Jakob Wurth, Sarah Morice, Samanta Kisele, Didier Surdez, Olivier O Delattre, Peter Karl Bode, Marco Wachtel, Beat W Schäfer
Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. Molecular cancer therapeutics 23 (6) (2024)
Sara G Danielli, Jakob Wurth, Sarah Morice, Samanta Kisele, Didier Surdez, Olivier O Delattre, Peter Karl Bode, Marco Wachtel, Beat W Schäfer
Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. Molecular cancer therapeutics 23 (6) (2024)
Sara G Danielli, Jakob Wurth, Sarah Morice, Samanta Kisele, Didier Surdez, Olivier O Delattre, Peter Karl Bode, Marco Wachtel, Beat W Schäfer
Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. Molecular cancer therapeutics 23 (6) (2024)